Gastric / GEJ adenocarcinoma · line 2 · Paclitaxel + Ramucirumab (RAINBOW) — 2L gastric/GEJ
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-PACLITAXEL-RAMUCIRUMAB-GASTRIC |
| ID | IND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-GASTRIC |
| Sources | SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Notes
STUB — pending Co-Lead sign-off. Standard-track 2L for HER2-negative metastatic gastric. Paclitaxel weekly monotherapy is the realistic fallback when ramucirumab funding unavailable in Ukraine (NSZU does not reimburse ramucirumab for gastric).
Used By
Algorithms
ALGO-GASTRIC-2L- ALGO-GASTRIC-2L